Dacomitinib Nitroso
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Dacomitinib is used to treat non-small cell lung cancer that has spread (metastatic) with an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation gene. Your doctor will use a test to check for the mutation before you receive this medicine.Dacomitinib Nitroso is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Dacomitinib Nitroso CAS NO:NA chemically represented as (E)-N-(4-((3-Chloro-4-fluorophenyl)(nitroso)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide . Synchemia is the leading manufacturing and exporter of Dacomitinib Nitroso . We supply Dacomitinib Nitroso with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142932 |
| CAS No | NA |
| Mol.F. | C24H27N5O6S |
| Mol.Wt. | 513.57 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142933 |
| CAS No | NA |
| Mol.F. | C16H24N4O4S |
| Mol.Wt. | 368.45 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142934 |
| CAS No | NA |
| Mol.F. | C19H24N4O7S |
| Mol.Wt. | 452.48 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142935 |
| CAS No | NA |
| Mol.F. | C16H19N3O3 |
| Mol.Wt. | 301.35 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142936 |
| CAS No | NA |
| Mol.F. | C16H20N4O5S |
| Mol.Wt. | 380.42 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142937 |
| CAS No | NA |
| Mol.F. | C24H31N5O8S |
| Mol.Wt. | 549.60 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142938 |
| CAS No | NA |
| Mol.F. | C24H33N5O7S |
| Mol.Wt. | 535.62 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142939 |
| CAS No | NA |
| Mol.F. | C15H27N3O2 |
| Mol.Wt. | 281.40 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142940 |
| CAS No | NA |
| Mol.F. | C20H26N4O8S |
| Mol.Wt. | 482.51 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142941 |
| CAS No | NA |
| Mol.F. | C16H18ClN3O5S |
| Mol.Wt. | 399.85 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142942 |
| CAS No | NA |
| Mol.F. | C16H19N3O6S |
| Mol.Wt. | 381.40 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142943 |
| CAS No | NA |
| Mol.F. | C21H28N4O7S |
| Mol.Wt. | 480.54g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142944 |
| CAS No | NA |
| Mol.F. | C26H37N5O6S |
| Mol.Wt. | 547.67g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142945 |
| CAS No | NA |
| Mol.F. | C18H20N4O8S |
| Mol.Wt. | 452.44 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142946 |
| CAS No | NA |
| Mol.F. | C18H18N4O10S |
| Mol.Wt. | 482.42 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142947 |
| CAS No | NA |
| Mol.F. | C7H17N3O2 |
| Mol.Wt. | 175.2 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |